Anti-malaria drugs fail on the outskirts of Thailand-Myanmar

According to the reporters, drugs which were said to be used widely so as to treat Malaria are rapidly becoming less effective for the patients on the outskirts of Thailand and Myanmar.

It had been researched by the Wellcome researchers that the genetic mutations in the kelch gene of the malaria parasite had made the parasite resistant to the anti-malaria drug mefloquine and the drug artusenate.

These drugs are usually used in the combination so as to treat malaria. This treatment is known as artemisinin combination therapy, but it is now said to be declining.

The data had been analyzed from the 10 year study by the researchers of 1,005 patients with uncomplicated Plasmodium falciparam malaria at Shoklo Malaria Research Unit (SMRU) clinics on the edges of Thai-Myanmar.

As said by Professor Francois Nosten, Director of SMRU, “This study demonstrates for the first time that artemisinin resistance leads to failure of the artemisinin partner drug, in this case, mefloquine. This means that the first line artemisinin combination therapy introduced here in 1994 has finally fallen to resistance.”

A unit of the Bangkok based MORU; SMRU is based in the refugee camps and migrant communities along the Thai-Myanmar outskirts in northwest Thailand.

About The Author

Related posts